Drug Profile


Alternative Names: ATI-2042

Latest Information Update: 14 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARYx Therapeutics
  • Developer Espero BioPharma
  • Class Benzofurans; Class III antiarrhythmics; Small molecules
  • Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atrial fibrillation; Ventricular tachycardia

Most Recent Events

  • 13 Feb 2017 Budiodarone is still in phase II trials for Atrial fibrillation in USA, Canada and European Union
  • 13 Feb 2017 Armetheon has patent protection for budiodarone in USA
  • 13 Feb 2017 Armetheon plans a phase II trial for Atrial fibrillation and Ventricular tachycardia in USA in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top